<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/insider-buying-urogen-pharma-ltd-nasdaqurgn-ceo-purchases-1548-shares-of-stock.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T07:08:41+00:00"/>
    <meta property="og:title" content="Insider Buying: Urogen Pharma Ltd (NASDAQ:URGN) CEO Purchases 1,548 Shares of Stock"/>
    <meta property="og:description" content="Urogen Pharma Ltd (NASDAQ:URGN) CEO Elizabeth A. Barrett purchased 1,548 shares of the company’s stock in a transaction on Friday, November 15th. The stock was bought at an average cost of $26.00 per share, for a total transaction of $40,248.00. Following the acquisition, the chief executive officer now directly owns 1,548 shares of the company’s […]"/>
  </head>
  <body>
    <article>
      <h1>Insider Buying: Urogen Pharma Ltd (NASDAQ:URGN) CEO Purchases 1,548 Shares of Stock</h1>
      <address><time datetime="2019-11-21T07:08:41+00:00">21 Nov 2019, 07:08</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/urogen-pharma-ltd-logo.jpg"/>
      </figure>
      <p>Urogen Pharma Ltd (NASDAQ:URGN) CEO Elizabeth A. Barrett purchased 1,548 shares of the company’s stock in a transaction on Friday, November 15th. The stock was bought at an average cost of $26.00 per share, for a total transaction of $40,248.00. Following the acquisition, the chief executive officer now directly owns 1,548 shares of the company’s stock, valued at approximately $40,248. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/1668243/000120919119057044/xslF345X03/doc4.xml">this hyperlink</a>.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/URGN/insider-trades/">NASDAQ URGN</a> opened at $29.50 on Thursday. Urogen Pharma Ltd has a twelve month low of $20.72 and a twelve month high of $55.49. The stock has a market cap of $555.23 million, a price-to-earnings ratio of -6.15 and a beta of 1.12. The firm’s 50 day moving average price is $23.28 and its two-hundred day moving average price is $31.37.</p>
      <p>Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.20. On average, equities research analysts expect that Urogen Pharma Ltd will post -4.79 earnings per share for the current fiscal year.</p>
      <p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. United Services Automobile Association grew its position in Urogen Pharma by 0.9% during the 2nd quarter. United Services Automobile Association now owns 50,605 shares of the company’s stock worth $1,819,000 after purchasing an additional 470 shares in the last quarter. Rhumbline Advisers grew its position in Urogen Pharma by 4.4% during the 3rd quarter. Rhumbline Advisers now owns 22,010 shares of the company’s stock worth $524,000 after purchasing an additional 931 shares in the last quarter. Harel Insurance Investments &amp; Financial Services Ltd. grew its position in Urogen Pharma by 50.0% during the 2nd quarter. Harel Insurance Investments &amp; Financial Services Ltd. now owns 3,000 shares of the company’s stock worth $108,000 after purchasing an additional 1,000 shares in the last quarter. Altshuler Shaham Ltd grew its position in Urogen Pharma by 4.8% during the 2nd quarter. Altshuler Shaham Ltd now owns 25,892 shares of the company’s stock worth $931,000 after purchasing an additional 1,194 shares in the last quarter. Finally, Bank Hapoalim BM grew its position in Urogen Pharma by 4.9% during the 3rd quarter. Bank Hapoalim BM now owns 27,230 shares of the company’s stock worth $653,000 after purchasing an additional 1,260 shares in the last quarter. Hedge funds and other institutional investors own 73.27% of the company’s stock.</p>
      <p>Several research analysts have issued reports on URGN shares. Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Monday, November 11th. HC Wainwright set a $75.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Monday, October 21st. Stifel Nicolaus set a $41.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Sunday, October 20th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=URGN">ValuEngine</a> raised Urogen Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 26th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $51.86.</p>
      <p>
        <b>About Urogen Pharma</b>
      </p>
      <p>UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/growth-stocks-what-they-are/">Growth Stocks</a></p>
    </article>
  </body>
</html>